

ARMSTRONG ERNEST
Form SC 13D/A
February 23, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No.1) *

Biogenetech Corp.

(Name of Issuer)
Common Stock

(Title of Class of Securities)

09063N 10 4

(CUSIP Number)

Chaslav Radovich, 2445 McCabe Way, Suite 150, Irvine, CA 92614
(949) 757-0001

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

February 19, 2003

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. []

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See ss.240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: ARMSTRONG ERNEST - Form SC 13D/A

CUSIP No. 09063N 10 4

1. Names of Reporting Persons. I.R.S. Identification
Nos. of above persons (entities only).

Ernest Armstrong

2. Check the Appropriate Box if a Member of a Group (See
Instructions)

(a) -----

(b) -----

3. SEC Use Only

4. Source of Funds (See Instructions) 00

5. Check if Disclosure of Legal Proceedings Is Required
Pursuant to Items 2(d) or 2(e)

6. Citizenship or Place of Organization U.S.

Number of 7. Sole Voting Power 100,000
Shares -----

Beneficially 8. Shared Voting Power 2,020,000
Owned by -----

Each 9. Sole Dispositive Power 100,000
Reporting -----

Edgar Filing: ARMSTRONG ERNEST - Form SC 13D/A

Person 10. Shared Dispositive Power 2,020,000

With

11. Aggregate Amount Beneficially Owned by Each Reporting
Person 2,120,000

12. Check if the Aggregate Amount in Row (11) Excludes
Certain Shares (See Instructions)

13. Percent of Class Represented by Amount in Row (11)
10.6%

14. Type of Reporting Person (See Instructions) IN

ITEM 1. SECURITY AND ISSUER

This statement relates to shares of the common stock, \$.001 par value of Biogenetech Corp., a Nevada corporation (the "Issuer"). The principal executive offices of the Issuer are located at 2445 McCabe Way, Suite 150, Irvine, CA 92614.

ITEM 2. IDENTITY AND BACKGROUND

(a) Name: Ernest Armstrong
(b) Business Address: 2445 McCabe Way, Suite 150, Irvine,
CA 92614
(c) Present Principal Occupation: Vice President of the Issuer.
(d) Disclosure of Criminal Proceedings: none
(e) Disclosure of Civil Proceedings: none
(f) Citizenship: U.S.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

Gene Pharmaceuticals, LLC, which is controlled by Ernest Armstrong, acquired 20,000 shares of the Issuer's shares pursuant to an anti-dilution provision in a

Edgar Filing: ARMSTRONG ERNEST - Form SC 13D/A

contract between the Issuer and Gene Pharmaceuticals. This transaction results in Mr. Armstrong owning 100,000 shares of the Issuer's common stock directly and personally, and 2,020,000 shares as managing member and majority owner of Gene Pharmaceuticals, LLC.

ITEM 4. PURPOSE OF TRANSACTION

Gene Pharmaceuticals, LLC acquired 20,000 shares pursuant to an anti-dilution provision in a contract between the Issuer and Gene Pharmaceuticals, resulting in the following distribution of ownership: Mr. Armstrong owns 100,000 shares of the Issuer's common stock directly and personally, and 2,020,000 shares as managing member and majority owner of Gene Pharmaceuticals, LLC.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

Mr. Armstrong beneficially owns a total of 2,120,000 shares of the Issuer's common stock as follows:

(a) Ernest Armstrong, sole officer and director of the Issuer, owns 100,000 shares individually, which comprises 0.5% of the Issuer's outstanding common stock, and 2,020,000 shares as sole owner of Gene Pharmaceuticals, LLC. Gene Pharmaceuticals, LLC directly owns 2,020,000 shares of the Issuer's common stock which comprises 10.1% of the Issuer's total issued and outstanding shares.

(b) Ernest Armstrong has sole voting and dispositive power as to the 100,000 shares he owns individually and as to the 2,020,000 shares which he controls as managing member and majority owner of Gene Pharmaceuticals, LLC.

(c) None.

(d) Not Applicable.

(e) Not Applicable.

ITEM 6. CONTACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

None.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

None.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 20, 2004

Date

Edgar Filing: ARMSTRONG ERNEST - Form SC 13D/A

/s/ Ernest Armstrong

Ernest Armstrong

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

ATTENTION: INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT
CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001)